🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

Crude Oil Rises Over 3%; US Home Prices Increase In October

Published 26/12/2023, 17:20
Crude Oil Rises Over 3%; US Home Prices Increase In October
US500
-
GC
-
HG
-
CL
-
IXIC
-
SSYS
-
AZN
-

Benzinga - by Avi Kapoor, Benzinga Staff Writer.

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Tuesday.

The Dow traded up 0.34% to 37,511.87 while the NASDAQ rose 0.43% to 15,057.13. The S&P 500 also rose, gaining, 0.34% to 4,770.79.

Check This Out: Top 3 Tech And Telecom Stocks That Could Blast Off In December

Leading and Lagging Sectors

Energy shares jumped by 0.8% on Tuesday.

In trading on Tuesday, health care shares fell by 0.1%.

Top Headline

The S&P CoreLogic Case-Shiller 20-city home price index rose by 4.9% year-over-year in October, recording the largest surge since Nov. 2022.

Equities Trading UP

Gracell Biotechnologies Inc. (NASDAQ: GRCL) shares shot up 59% to $9.88. AstraZeneca Plc (NASDAQ: AZN) agreed to acquire Gracell Biotechnologies, further strengthening AstraZeneca's cell therapy portfolio.

Shares of Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) got a boost, surging 93% to $2.31 after the company announced 95% accuracy results for HYLA blood sensor.

Stratasys Ltd. (NASDAQ: SSYS) shares were also up, gaining 11% to $14.51 after the company confirmed that it received a preliminary proposal from Nano Dimension to purchase all of its outstanding shares at $16.50 per share in cash.

Equities Trading DOWN

Adit EdTech Acquisition Corp. (NASDAQ: ADEX) shares dropped 18% to $4.1001. Adit EdTech Acquisition announced intention to voluntarily de-list from NYSE American.

Shares of Milestone Pharmaceuticals Inc. (NASDAQ: MIST) were down 34% to $1.9050 after the company announced that it received a Refusal to File letter from the FDA for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was down, falling 12% to $0.5281. Oncternal Therapeutics updated the status of its Phase 1/2 study of ONCT-808, a ROR1-targeting autologous CAR T, in patients with relapsed or refractory aggressive B-cell lymphoma.

Also Check This Out: Beat Inflation With These 3 High-Yielding Dividend Stocks In Energy Sector From Wall Street's Most Accurate Analysts

Commodities

In commodity news, oil traded up 3.3% to $76.02 while gold traded up 0.1% at $2,070.10.

Silver traded down 0.3% to $24.495 on Tuesday while copper rose 0.4% to $3.9190.

Asia Pacific Markets

Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 gaining 0.16%, and China’s Shanghai Composite Index falling 0.68%. India’s S&P BSE Sensex, meanwhile, rose 0.32%.

India's current account deficit shrank to $8.3 billion in the July-September quarter from $30.9 billion in the year-ago quarter. Japan’s unemployment rate came in unchanged at 2.5% in November.

Economics

The Chicago Fed National Activity Index increased to +0.03 in November, versus a revised reading of -0.66 in the prior month.

The S&P CoreLogic Case-Shiller 20-city home price index rose by 4.9% year-over-year in October, recording the largest surge since Nov. 2022.

The FHFA house price index rose by 0.3% from the prior month in October.

Now Read This: How To Earn $500 A Month From Nike Stock Following Quarterly Report

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.